Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer

被引：0
作者：
Gaya Spolverato
Fabio Bagante
Cecilia G. Ethun
George Poultsides
Thuy Tran
Kamran Idrees
Chelsea A. Isom
Ryan C. Fields
Bradley Krasnick
Emily Winslow
Clifford Cho
Robert C. G. Martin
Charles R. Scoggins
Perry Shen
Harveshp D. Mogal
Carl Schmidt
Eliza Beal
Ioannis Hatzaras
Rivfka Shenoy
Shishir K. Maithel
Timothy M. Pawlik
机构：
[1] The Ohio State University Wexner Medical Center,Professor and Chair Department of Surgery, The Urban Meyer III and Shelley Meyer Chair in Cancer Research
[2] Emory University,Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute
[3] Stanford University Medical Center,Department of Surgery
[4] Vanderbilt University Medical Center,Division of Surgical Oncology, Department of Surgery
[5] Washington University School of Medicine,Department of Surgery
[6] University of Wisconsin School of Medicine and Public Health,Department of Surgery
[7] University of Louisville,Division of Surgical Oncology, Department of Surgery
[8] Wake Forest University,Department of Surgery
[9] The Ohio State University Comprehensive Cancer Center,Division of Surgical Oncology
[10] New York University,Department of Surgery
来源：
World Journal of Surgery | 2017年 / 41卷
关键词：
Cholangiocarcinoma; Gallbladder Carcinoma; Biliary Tract Cancer; Intrahepatic Cholangiocarcinoma; Preoperative Biliary Drainage;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：224 / 231
页数：7
相关论文
共 52 条
[1]  
Valero V(2012)Management of perihilar cholangiocarcinoma in the era of multimodal therapy Expert Rev Gastroenterol Hepatol 6 481-495
[2]  
Kanthan R(2015)Gallbladder cancer in the 21st century J Oncol 2015 967472-229
[3]  
Hansel DE(2003)Identification of novel cellular targets in biliary tract cancers using global gene expression technology Am J Pathol 163 217-712
[4]  
Tannapfel A(2003)Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma Gut 52 706-1281
[5]  
Valle J(2010)Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 1273-592
[6]  
Friend E(2011)Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21 Br J Cancer 104 587-1651
[7]  
El-Khoueiry AB(2012)SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma Invest New Drugs 30 1646-887
[8]  
El-Khoueiry AB(2014)S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma Br J Cancer 110 882-2622
[9]  
Ben-Josef E(2015)SWOG S0809: a Phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma J Clin Oncol 33 2617-517
[10]  
Jarnagin WR(2001)Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma Ann Surg 234 507-107
123456